Market Place
Sourcing Support
Roche to Start Ph 2 Petrelintide-Enicepatide Combo Trial in 2026
06 Jun 2026 //
ENDPOINTS
ZUPREME-1 Ph2 Data Back Petrelintide for Weight Management at ADA
05 Jun 2026 //
GLOBENEWSWIRE
Roche To Showcase Obesity Portfolio Progress At ADA 2026 Sessions
01 Jun 2026 //
GLOBENEWSWIRE
Zealand Pharma to Present Data at ADA 2026
27 May 2026 //
GLOBENEWSWIRE
Zealand, Roche Advance Petrelintide Amylin to Phase 3
29 Apr 2026 //
FIRSTWORD PHARMA
Roche Backs Amylin Drug for Low-Side-Effect Obesity Care
23 Apr 2026 //
BIOSPACE
Zealand`s Zupreme serves up to 10.7% mean weight loss
06 Mar 2026 //
GLOBENEWSWIRE
Roche Reports Positive Phase II Results For Petrelintide
05 Mar 2026 //
GLOBENEWSWIRE
Genentech Announces Positive Phase II Results for Petrelintide
05 Mar 2026 //
PHARMIWEB
Zealand Pharma Announces Financial Results For The Full Year 2025
19 Feb 2026 //
GLOBENEWSWIRE
Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36
10 Feb 2026 //
PR NEWSWIRE
Zealand Pharma Unveils Metabolic Frontier 2030 Strategy
11 Dec 2025 //
GLOBENEWSWIRE
Ascletis Chooses ASC36, A Monthly Subcutaneous Amylin Agonist
30 Oct 2025 //
PR NEWSWIRE
Zealand Pharma May Sell Future Obesity Drug Direct to Patients
23 Sep 2025 //
REUTERS
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.